Citation | Zhu, F; Wang, Y; Du, Q; Ge, W; Li, Z; Wang, X; Fu, C; Luo, L; Tian, S; Ma, H; Zheng, J; Zhang, Y; Sun, X; He, S; Zhang, X Structural optimization of aminopyrimidine-based CXCR4 antagonists. Eur J Med Chem187:0 (2020) [PubMed] Article |
---|
Synonyms: | 1,1''-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane} | 1,4,8,11-tetraazacyclotetradecanyl[4-(1,4,8,11-tetraazacyclotetradecanylmethyl)phenyl]methane | 1,4,8,11-tetraazacyclotetradecanyl[4-(1,4,8,11-tetraazacyclotetradecanylmethyl)phenyl]methane(8HBr.2H2O) | 1,4-bis((1,4,8,11-tetraazacyclotetradecan-1-yl)methyl)benzene | 11''-xylyl bis-1,4,8,11-tetraazacyclotetradecane | 11-{4-[4,8, 11-1,4,8,11tetraaza-cyclotetradec-1-ylmethyl]-benzyl}-1,4,8,11tetraaza-cyclotetradecane-1,4,8-tricarboxylic acid tri-tert-butyl ester | AMD-3100 | CHEMBL18442 | CHEMBL2311089 | PLERIXAFOR | PLERIXAFOR OCTAHYDROCHLORIDE | US9205085, MSX-162 |